| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 65.4 | 56.4 |
| Profit before tax | -37.9 | -41.0 |
| Net income | -53.5 | 21.6 |
| EPS (diluted, $ a share) | $-0.07 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +15.9% |
|---|---|
| Operating margin | -48.0% |
10-Q filed with the SEC, NASDAQ: OPK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Opko Health, Inc.: key numbers
- Share price
- $1.62Close, Nov 17
- Market cap
- $1.2B
- Shares outstanding
- 742.51MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Opko Health, Inc.
All →Opko Health Director John A. Paganelli Sells $16.7K of Stock
John A. Paganelli, Director, sold 9,175 shares of Opko Health, Inc. at $1.82 a share, worth $16.7K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $16.7K
- Shares
- 9,175
- Price
- $1.82
- Role
- Director
- Holding change
- -100.0%
- Trade date
- Nov 5, 2026
Opko Health Financial Results
OPKO Health reported its third quarter 2026 financial results, highlighting a pending $722 million sale of its BioReference diagnostic operations to Labcorp. The company also expanded its financing with HealthCare Royalty by $125 million and advanced several clinical programs, including dosing the first participant in a Phase 1/2a trial for acromegaly.
- Term
- Q3 2026
Opko Health Divestiture to Laboratory Corporation of America Holdings for $722M
OPKO Health and its subsidiary BioReference Health entered into a definitive agreement to sell certain assets of their clinical and anatomic pathology laboratory testing business to Labcorp for $722 million in cash. The deal includes clinical and women’s health testing, urology, and the proprietary 4Kscore prostate cancer test, with OPKO eligible for up to an additional $150 million in milestone payments over ten years based on 4Kscore revenue. The transaction is subject to HSR Clearance and customary closing conditions, with a target completion date by April 14, 2027.
- Value
- $722M
- Counterparty
- Laboratory Corporation of America Holdings
- Term
- up to 10 years
Opko Health $121M Debt Financing with U.S. Bank Trust Company, National Association
OPKO Health announced that its 3.75% Convertible Senior Notes due 2029 have become convertible by holders through December 31, 2026, after the stock price exceeded 130% of the conversion price for a specified period. The company has elected to settle these conversion obligations in shares of common stock rather than cash. Approximately $121 million in principal amount of these notes remains outstanding.
- Value
- $121M
- Counterparty
- U.S. Bank Trust Company, National Association